Sex-specific predictive values of biomarkers for immunotherapy efficacy in lung adenocarcinoma
Chi, T.; Jia, M.
Show abstract
It remains a challenge to accurately predict patient responses to tumor immunotherapy, although various biomarkers have been proposed to predict patient responses to anti-PD-1 therapy. Here by integrating genomic, transcriptomic, proteomic and clinical phenotype data from three immunotherapeutic cohorts and a multiple-dimensional dataset of The Cancer Genome Atlas (TCGA) project, we uncovered a profound effect of Sex on the predictive values of conventional biomarkers in lung adenocarcinoma (LUAD): only in females were nonsynonymous mutation burden (TMB), neoantigen burden, smoking signature, KRAS mutations (especially G12C and G12V) or tumor microenvironment robustly correlated with anti-PD-1 efficacy; the correlations in males were either absent or weaker. We propose that Sex be considered in conjunction with conventional biomarkers when predicting immunotherapy efficacy, and conversely, conventional biomarkers be carefully controlled for when attempting to dissect the impact of Sex on immunotherapy efficacy.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- A Genomically and Clinically Annotated Patient Derived Xenograft (PDX) Resource for Preclinical Research in Non-Small Cell Lung Cancer 96%
- Germline and somatic genetic variants in the p53 pathway interact to affect cancer risk, progression and drug response 94%
- Quantifying T- and B-cell immune receptor distribution diversity to uncover their clinical relevance in clear cell renal cell carcinoma 94%
Similar papers in this journal
- Myeloid cell-associated resistance to PD-1/PD-L1 blockade in urothelial cancer revealed through bulk and single-cell RNA sequencing 96%
- Elucidating the heterogeneity of immunotherapy response and immune-related toxicities by longitudinal ctDNA and immune cell compartment tracking in lung cancer 95%
- Circulating tumor DNA analysis in advanced urothelial carcinoma: insights from biological analysis and extended clinical follow-up 95%
Similar papers in this journal
- Clinically-relevant treatment of PDX models reveals patterns of neuroblastoma chemoresistance 94%
- CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon restoration of RB function in malignant peripheral nerve sheath tumors 94%
- Classical oncogene family Myc defines unappreciated distinct lineage states of small cell lung cancer 94%
Similar papers in this journal
- Predicting tumor immune microenvironment and checkpoint therapy response of head & neck cancer patients from blood immune single-cell transcriptomics 94%
- Tumor suppressor PLK2 may serve as a biomarker in triple-negative breast cancer for improved response to PLK1 therapeutics 94%
- EZH2 inhibition promotes tumor immunogenicity in lung squamous cell carcinomas 94%
Similar papers in this journal
- Single Cell RNA-sequencing of BCG naive and recurrent non-muscle invasive bladder cancer reveals a CD6/ALCAM mediated immune-suppressive pathway 95%
- Generating immunogenomic data-guided virtual patients using a QSP model to predict response of advanced NSCLC to PD-L1 inhibition 94%
- A single-cell based precision medicine approach using glioblastoma patient-specific models 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.